Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akshay B Jain

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Canadian Journal of Diabetes|February 4, 2026
The IDEA Framework: A Consensus-Based Model for Integrating Continuous Glucose Monitoring into Pharmacy Practice for Diabetes CareAaron Sihota, Akshay B Jain, Alicia Chin, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|November 13, 2024
Oral Semaglutide Use in Type 2 Diabetes: A Pooled Analysis of Clinical and Patient-Reported Outcomes from Seven PIONEER REAL Prospective Real-World StudiesGottfried Rudofsky, Hanan Amadid, Uffe Christian Braae, et al.
Lancet (London, England)|June 7, 2026
Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 studyJulio Rosenstock, Liana K Billings, Reena Gajria, et al.
International Journal of Clinical Practice|September 25, 2020
Switching between GLP-1 receptor agonists in clinical practice: Expert consensus and practical guidanceAkshay B Jain, Amar Ali, Juan J Gorgojo Martínez, et al.
The Lancet. Diabetes & Endocrinology|June 7, 2026
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a studyVanita R Aroda, Raffaella Buzzetti, Stine-Mathilde Dalskov, et al.
International Journal of Environmental Research and Public Health|April 26, 2025
Impact of the COVID-19 Pandemic and Control Measures on Screening and Diagnoses of Type 2 Diabetes in British ColumbiaBushra Mahmood, Gordon Li, Julia Li, et al.
The Lancet. Diabetes & Endocrinology|June 7, 2026
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 studyJohn B Buse, Harpreet S Bajaj, Stine-Mathilde Dalskov, et al.
Mayo Clinic Proceedings|April 3, 2025
Advance Insulin Injection Technique and Education With FITTER Forward Expert RecommendationsDavid C Klonoff, Lori Berard, Denise Reis Franco, et al.
Canadian Journal of Diabetes|June 15, 2023
Diabetes and Mental Health, David J Robinson, Kimberley Hanson, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Canadian Journal of Diabetes|February 4, 2026
The IDEA Framework: A Consensus-Based Model for Integrating Continuous Glucose Monitoring into Pharmacy Practice for Diabetes CareAaron Sihota, Akshay B Jain, Alicia Chin, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|November 13, 2024
Oral Semaglutide Use in Type 2 Diabetes: A Pooled Analysis of Clinical and Patient-Reported Outcomes from Seven PIONEER REAL Prospective Real-World StudiesGottfried Rudofsky, Hanan Amadid, Uffe Christian Braae, et al.
Lancet (London, England)|June 7, 2026
Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 studyJulio Rosenstock, Liana K Billings, Reena Gajria, et al.
International Journal of Clinical Practice|September 25, 2020
Switching between GLP-1 receptor agonists in clinical practice: Expert consensus and practical guidanceAkshay B Jain, Amar Ali, Juan J Gorgojo Martínez, et al.
The Lancet. Diabetes & Endocrinology|June 7, 2026
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a studyVanita R Aroda, Raffaella Buzzetti, Stine-Mathilde Dalskov, et al.
International Journal of Environmental Research and Public Health|April 26, 2025
Impact of the COVID-19 Pandemic and Control Measures on Screening and Diagnoses of Type 2 Diabetes in British ColumbiaBushra Mahmood, Gordon Li, Julia Li, et al.
The Lancet. Diabetes & Endocrinology|June 7, 2026
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 studyJohn B Buse, Harpreet S Bajaj, Stine-Mathilde Dalskov, et al.
Mayo Clinic Proceedings|April 3, 2025
Advance Insulin Injection Technique and Education With FITTER Forward Expert RecommendationsDavid C Klonoff, Lori Berard, Denise Reis Franco, et al.
Canadian Journal of Diabetes|June 15, 2023
Diabetes and Mental Health, David J Robinson, Kimberley Hanson, et al.
Pageof 2